MA52884A - Anticorps anti-il-11 - Google Patents

Anticorps anti-il-11

Info

Publication number: MA52884A
Authority: MA; Morocco
Prior art keywords: antibodies
Prior art date: 2018-06-13

Application number

MA052884A

Other languages

English (en)

Inventor

Stuart Alexander Cook

Sebastian Schaefer

Original Assignee

Boehringer Ingelheim Int

Nat Univ Singapore

Singapore Health Serv Pte Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-06-13

Filing date

2019-06-13

Publication date

2021-04-21

2019-06-13 Application filed by Boehringer Ingelheim Int, Nat Univ Singapore, Singapore Health Serv Pte Ltd filed Critical Boehringer Ingelheim Int

2021-04-21 Publication of MA52884A publication Critical patent/MA52884A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pathology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Hospice & Palliative Care (AREA)

MA052884A 2018-06-13 2019-06-13 Anticorps anti-il-11 MA52884A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1809699.0A GB201809699D0 (en)	2018-06-13	2018-06-13	IL-11 antibodies

Publications (1)

Publication Number	Publication Date
MA52884A true MA52884A (fr)	2021-04-21

Family

ID=63042160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA052884A MA52884A (fr)	2018-06-13	2019-06-13	Anticorps anti-il-11

Country Status (25)

Country	Link
US (4)	US11084874B2 (fr)
EP (1)	EP3807314A1 (fr)
JP (2)	JP2021535733A (fr)
KR (1)	KR20210031690A (fr)
CN (1)	CN113056481A (fr)
AU (2)	AU2019286795B2 (fr)
BR (1)	BR112020025443A2 (fr)
CA (1)	CA3102483A1 (fr)
CL (1)	CL2020003223A1 (fr)
CO (1)	CO2020015383A2 (fr)
CR (1)	CR20210009A (fr)
DO (2)	DOP2020000245A (fr)
EA (1)	EA202092668A1 (fr)
EC (1)	ECSP21000695A (fr)
GB (1)	GB201809699D0 (fr)
IL (1)	IL279356A (fr)
JO (1)	JOP20200309A1 (fr)
MA (1)	MA52884A (fr)
MX (1)	MX2020013583A (fr)
PE (1)	PE20211498A1 (fr)
PH (1)	PH12020552232A1 (fr)
SA (1)	SA520420801B1 (fr)
SG (1)	SG11202011782XA (fr)
TW (1)	TW202003560A (fr)
WO (1)	WO2019238882A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201522186D0 (en)	2015-12-16	2016-01-27	Singapore Health Services Pte Ltd And Nat University Of Singapore The	Treatment of fibrosis
US20180186871A1 (en)	2016-12-16	2018-07-05	Singapore Health Services Pte Ltd.	Il-11 antibodies
GB201621439D0 (en)	2016-12-16	2017-02-01	Singapore Health Services Pte Ltd And Nat Univ Of Singapore	IL-11Ra Antibodies
WO2018119142A1 (fr)	2016-12-21	2018-06-28	Amgen Inc.	Formulations d'anticorps anti-tnf alpha
GB201716733D0 (en) *	2017-10-12	2017-11-29	Nat Univ Singapore	Treatment of SMC mediated disease
EP3914621A1 (fr)	2019-01-21	2021-12-01	Singapore Health Services Pte. Ltd.	Traitement d'hépatotoxicité
GB201902419D0 (en)	2019-02-22	2019-04-10	Singapore Health Serv Pte Ltd	Treatment of kidney injury
BR112021021921A2 (pt)	2019-05-03	2021-12-28	Nat Univ Singapore	Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
GB202009292D0 (en)	2020-06-18	2020-08-05	Singapore Health Serv Pte Ltd	Treatment and prevention of disease caused by type IV collagen dysfunction
CN116601169A (zh) *	2020-07-20	2023-08-15	生物综合治疗有限公司	针对马尔堡病毒的广泛中和结合分子
EP4198055A4 (fr) *	2020-08-13	2024-08-28	Sunshine Lake Pharma Co., Ltd.	Anticorps d'il-11 et son utilisation
GB202017244D0 (en)	2020-10-30	2020-12-16	Nat Univ Singapore	Methods to extend health-span and treat age-related diseases
CN114681592A (zh) *	2020-12-31	2022-07-01	天境生物科技(杭州)有限公司	包含可溶性gp130二聚体的制剂和使用方法
CN113980129B (zh) *	2021-01-15	2023-07-28	东大生物技术(苏州)有限公司	一组il-11单克隆抗体及其医药用途
JP2024512279A (ja)	2021-02-26	2024-03-19	バイエルアクチェンゲゼルシャフト	異常子宮出血の処置における使用のためのｉｌ－１１又はｉｌ－１１ｒａの阻害剤
WO2023006765A1 (fr)	2021-07-26	2023-02-02	Boehringer Ingelheim International Gmbh	Traitement et prévention d'une maladie hépatique alcoolique
US20250002574A1 (en) *	2021-08-12	2025-01-02	Sunshine Lake Pharma Co., Ltd.	Il-11 humanized antibody and application thereof
MX2024002611A (es)	2021-08-30	2024-05-29	Lassen Therapeutics 1 Inc	Anticuerpos anti-il-11ra.
US20250082608A1 (en)	2021-12-16	2025-03-13	Singapore Health Services Pte Ltd.	Treatment and prevention of glomerular disease
CN116891528A (zh)	2022-01-29	2023-10-17	迈威(上海)生物科技股份有限公司	一种抗白介素-11的抗体及其应用
GB202218388D0 (en)	2022-12-07	2023-01-18	Vvb Bio Pte Ltd	GP130 antigen-binding molecules
WO2024146458A1 (fr)	2023-01-06	2024-07-11	广东东阳光药业股份有限公司	Anticorps humanisé anti-cytokine il-11
EP4702047A1 (fr)	2023-04-25	2026-03-04	VVB Bio Pte. Ltd.	Anticorps anti-il-11
CN120518761B (zh) *	2023-06-05	2025-12-26	北京东方百泰生物科技股份有限公司	一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en)	2023-07-19	2023-08-30	Vvb Bio Pte Ltd	GP130 antigen-binding molecules
WO2025026206A1 (fr) *	2023-07-28	2025-02-06	迈威(上海)生物科技股份有限公司	Utilisation d'anticorps anti-interleukine-11 dans la préparation d'un médicament pour le traitement de tumeurs
WO2025108343A1 (fr) *	2023-11-22	2025-05-30	上海华奥泰生物药业股份有限公司	Protéine de liaison à l'antigène ciblant il-11
TW202528345A (zh) *	2024-01-02	2025-07-16	大陸商上海華奧泰生物藥業股份有限公司	靶向ｉｌ－１１和ｔｓｌｐ的多特異性分子
GB202405551D0 (en)	2024-04-19	2024-06-05	Vvb Bio Pte Ltd	Combination treatment
GB202408044D0 (en)	2024-06-06	2024-07-24	Vvb Bio Pte Ltd	gp130 antigen-binding molecules
WO2026001793A1 (fr) *	2024-06-27	2026-01-02	上海华奥泰生物药业股份有限公司	Protéine de liaison à l'antigène ciblant il-11 et son utilisation
CN119119262B (zh) *	2024-08-02	2025-05-02	杭州曼迪生物科技有限公司	一种干细胞冻干粉及其在制备药物或者化妆品中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2399148A1 (fr) *	2000-02-10	2001-08-16	Abbott Laboratories	Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
US8518888B2 (en) *	2008-10-14	2013-08-27	Csl Limited	Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
GB201522186D0 (en)	2015-12-16	2016-01-27	Singapore Health Services Pte Ltd And Nat University Of Singapore The	Treatment of fibrosis
RU2016125115A (ru) *	2016-06-23	2017-12-28	Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН)	Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
US20180186871A1 (en) *	2016-12-16	2018-07-05	Singapore Health Services Pte Ltd.	Il-11 antibodies
RU2016151730A (ru) *	2016-12-28	2018-06-29	Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН)	Антитела для лабораторной диагностики концентрации интерлейкина-11

2018
- 2018-06-13 GB GBGB1809699.0A patent/GB201809699D0/en not_active Ceased
2019
- 2019-06-13 TW TW108120516A patent/TW202003560A/zh unknown
- 2019-06-13 MA MA052884A patent/MA52884A/fr unknown
- 2019-06-13 PE PE2020001992A patent/PE20211498A1/es unknown
- 2019-06-13 AU AU2019286795A patent/AU2019286795B2/en active Active
- 2019-06-13 JP JP2020568955A patent/JP2021535733A/ja active Pending
- 2019-06-13 CA CA3102483A patent/CA3102483A1/fr active Pending
- 2019-06-13 BR BR112020025443-6A patent/BR112020025443A2/pt unknown
- 2019-06-13 EA EA202092668A patent/EA202092668A1/ru unknown
- 2019-06-13 EP EP19734285.0A patent/EP3807314A1/fr active Pending
- 2019-06-13 JO JOP/2020/0309A patent/JOP20200309A1/ar unknown
- 2019-06-13 CR CR20210009A patent/CR20210009A/es unknown
- 2019-06-13 KR KR1020217000825A patent/KR20210031690A/ko not_active Ceased
- 2019-06-13 MX MX2020013583A patent/MX2020013583A/es unknown
- 2019-06-13 SG SG11202011782XA patent/SG11202011782XA/en unknown
- 2019-06-13 WO PCT/EP2019/065598 patent/WO2019238882A1/fr not_active Ceased
- 2019-06-13 CN CN201980054506.1A patent/CN113056481A/zh active Pending
- 2019-06-13 US US16/440,840 patent/US11084874B2/en active Active
2020
- 2020-12-09 CO CONC2020/0015383A patent/CO2020015383A2/es unknown
- 2020-12-10 IL IL279356A patent/IL279356A/en unknown
- 2020-12-11 CL CL2020003223A patent/CL2020003223A1/es unknown
- 2020-12-11 DO DO2020000245A patent/DOP2020000245A/es unknown
- 2020-12-13 SA SA520420801A patent/SA520420801B1/ar unknown
- 2020-12-13 PH PH12020552232A patent/PH12020552232A1/en unknown
2021
- 2021-01-06 EC ECSENADI2021695A patent/ECSP21000695A/es unknown
- 2021-03-25 US US17/212,456 patent/US20210230266A1/en active Pending
2024
- 2024-03-01 US US18/592,665 patent/US20240190953A1/en active Pending
- 2024-03-01 US US18/592,746 patent/US20240270837A1/en active Pending
- 2024-05-09 JP JP2024076402A patent/JP2024105466A/ja active Pending
- 2024-10-29 DO DO2024000220A patent/DOP2024000220A/es unknown
2026
- 2026-03-05 AU AU2026201704A patent/AU2026201704A1/en active Pending

Also Published As

Publication number	Publication date
IL279356A (en)	2021-01-31
PE20211498A1 (es)	2021-08-11
GB201809699D0 (en)	2018-08-01
KR20210031690A (ko)	2021-03-22
PH12020552232A1 (en)	2021-06-28
AU2026201704A1 (en)	2026-03-26
JP2021535733A (ja)	2021-12-23
WO2019238882A1 (fr)	2019-12-19
SG11202011782XA (en)	2020-12-30
CL2020003223A1 (es)	2021-07-30
US11084874B2 (en)	2021-08-10
AU2019286795A1 (en)	2021-01-28
CN113056481A (zh)	2021-06-29
CA3102483A1 (fr)	2019-12-19
US20240190953A1 (en)	2024-06-13
EP3807314A1 (fr)	2021-04-21
ECSP21000695A (es)	2021-03-31
MX2020013583A (es)	2021-04-13
SA520420801B1 (ar)	2023-12-07
DOP2024000220A (es)	2025-02-28
JOP20200309A1 (ar)	2020-11-30
EA202092668A1 (ru)	2021-05-18
AU2019286795B2 (en)	2026-03-12
US20240270837A1 (en)	2024-08-15
CO2020015383A2 (es)	2021-04-19
TW202003560A (zh)	2020-01-16
US20200031918A1 (en)	2020-01-30
DOP2020000245A (es)	2021-10-31
JP2024105466A (ja)	2024-08-06
CR20210009A (es)	2021-06-21
BR112020025443A2 (pt)	2021-03-16
US20210230266A1 (en)	2021-07-29

Publication	Publication Date	Title
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
EP3903817A4 (fr)	2022-08-17	Nouvel anticorps anti-ccr8
EP3784699A4 (fr)	2022-04-13	Anticorps anti-tl1a optimisés
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
MA52742A (fr)	2021-04-14	Anticorps bispécifiques dll3-cd3
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
EP3589313A4 (fr)	2021-05-19	Anticorps anti-tigit
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA52212A (fr)	2021-02-17	Anticorps multivalent
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
EP3684806A4 (fr)	2021-09-22	Nouveaux anticorps anti-cd3epsilon
MA52152A (fr)	2021-01-20	Anticorps
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
EP3752536A4 (fr)	2022-05-11	Anticorps anti-her2
EP3831851A4 (fr)	2022-04-27	Anticorps anti-btla
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
EP3484919A4 (fr)	2020-03-04	Anticorps anti-bêta-amyloïde
EP3399992A4 (fr)	2019-07-31	Anticorps autoréticulants
EP3596126A4 (fr)	2021-03-03	Nouveaux anticorps anti-trkb
MA56466A (fr)	2022-05-11	Anticorps anti-epha4
MA51135A (fr)	2021-03-24	Anticorps anti-alpha-synucléine